Treatment Pattern and Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients in Indonesia: Part of Asia-Pacific Breast Initiative II

Samuel Johny Haryono* -  Department of Surgical Oncology, Dharmais Hospital-National Cancer Center, Jakarta, Indonesia
Noorwati Sutandyo -  Department of Hematology and Medical Oncology, Dharmais Hospital-National Cancer Center, Jakarta, Indonesia
Ramadhan Karsono -  Department of Surgical Oncology, Dharmais Hospital-National Cancer Center, Jakarta, Indonesia
Bambang Karsono -  Department of Hematology and Medical Oncology, Dharmais Hospital-National Cancer Center, Jakarta, Indonesia
Denni Joko Purwanto -  Department of Surgical Oncology, Dharmais Hospital-National Cancer Center, Jakarta, Indonesia
Alban Dien -  Department of Surgical Oncology, Dharmais Hospital-National Cancer Center, Jakarta, Indonesia
Nugroho Prayogo -  Department of Hematology and Medical Oncology, Dharmais Hospital-National Cancer Center, Jakarta, Indonesia
Walta Gautama -  Department of Surgical Oncology, Dharmais Hospital-National Cancer Center, Jakarta, Indonesia

DOI : 10.33371/ijoc.v13i1.569

Background: Breast cancer is the most diagnosed cancer among Indonesian women. Adjuvant chemotherapy plays a crucial role in the management of early breast cancer patients, with docetaxel-based regimens as a cornerstone therapy. The Asia-Pacific breast initiative II registry was established to evaluate safety parameters of docetaxel-based regimens in the Asia-Pacific region within 2009–2013 period. The result from Indonesia population is presented in this study.

Methods: This study was a part of International, longitudinal, multicenter, and observational research which included a group of consecutive early breast cancer patients with an intermediate-to-high risk of recurrence that was being treated with various docetaxel-based (anthracycline and non-anthracycline) adjuvant chemotherapy regimens during 2009–2013 in real-world clinical settings.


Results: The analysis included 49 subjects (2.8% of total study population). Majority of subjects received non-anthracycline-containing regimen (79.6%). Docetaxel was mainly prescribed in combination (63.27%). Chemotherapy-related adverse events were reported in all subjects. Mean number of cycles received by subjects was 5.5 cycles with dose intensity of 23.78 mg/m2/week.


Conclusions: The Indonesian result, as part of the Asia-Pacific Breast Initiative II Registry, identified some important factors that are relevant to clinical practice, including patient’s characteristics and treatment pattern of docetaxel use as adjuvant chemotherapy regimens.


 

Keywords
early breast cancer, docetaxel, adverse event, registry, Indonesi
Full Text:
Article Info
Submitted: 2018-09-17
Published: 2019-04-15
Section: Research Articles
Article Statistics: 7 11